All included cancers |
|
Stage 0 v. ≥ stage I | 0.99 (0.71–1.38) | 0.95 | 1.00 (0.69–1.45) | 0.99 |
|
≤ stage I v. ≥ stage II | 0.99 (0.82–1.21) | 0.9 | 0.93 (0.75–1.16) | 0.5 |
|
≤ stage II v. ≥ stage III | 0.93 (0.77–1.12) | 0.5 | 0.95 (0.77–1.18) | 0.7 |
|
≤ stage III v. stage IV | 1.11 (0.89–1.39) | 0.4 | 1.20 (0.94–1.54) | 0.1 |
|
Included cancers† excluding female-only cancers‡ |
|
Stage 0 v. ≥ stage I | 1.01 (0.58–1.78) | 0.96 | 1.19 (0.61–2.32) | 0.6 |
|
≤ stage I v. ≥ stage II | 0.93 (0.74–1.17) | 0.5 | 0.86 (0.67–1.11) | 0.2 |
|
≤ stage II v. ≥ stage III | 0.89 (0.73–1.10) | 0.3 | 0.87 (0.69–1.10) | 0.2 |
|
≤ stage III v. stage IV | 1.04 (0.82–1.33) | 0.7 | 1.10 (0.84–1.43) | 0.5 |
|
Female-only cancers‡ |
|
Stage 0 v. ≥ stage I | 0.97 (0.62–1.52) | 0.9 | 0.75 (0.45–1.25) | 0.3 |
|
≤ stage I v. ≥ stage II | 1.21 (0.81–1.82) | 0.3 | 1.02 (0.62–1.68) | 0.9 |
|
≤ stage II v. ≥ stage III | 1.24 (0.66–2.30) | 0.5 | 1.22 (0.58–2.58) | 0.6 |
|
≤ stage III v. stage IV | 2.64 (1.20–5.81) | 0.02 | 2.87 (1.17–7.05) | 0.02 |